IT1208

IT1208 is a **defucosylated humanized monoclonal antibody targeting CD4**, developed to deplete CD4+ T cells and thereby remodel the T cell receptor (TCR) repertoire to enhance antitumor immune responses. By selectively removing CD4+ cells, IT1208 increases the population and tumor infiltration of CD8+ T cells, leading to reduced CD4/8 ratios and enabling robust antitumor activity. It is engineered for potent antibody-dependent cellular cytotoxicity (ADCC) and has shown preliminary efficacy signals—most notably in advanced solid tumors, including cases of colon, gastric, and esophageal cancers—in phase 1 trials. It was originally developed by Kyowa Kirin and is of interest both as a monotherapy and for potential combination with immune checkpoint inhibitors[1][3][4][5][6].

Other names

anti-CD4 mAbanti-CD-4 mAbanti-CD 4 mAbCD4-depleting antibodyCD-4-depleting antibodyCD 4-depleting antibody